1. Show article details.

    BRIEF-Edwards Lifesciences - pascal precision transcatheter valve repair system received CE Mark for treatment of mitral and tricuspid regurgitation

    Reuters – 8:35 AM ET 08/17/2022

    Edwards Lifesciences Corp (EW): * EDWARDS LIFESCIENCES (EW) - PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVED CE MARK FOR TREATMENT OF MITRAL AND TRICUSPID REGURGITATION Source text for Eikon: Further company coverage:

  2. Show article details.

    EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK

    PR Newswire – 8:30 AM ET 08/17/2022

    IRVINE, Calif. "Delivering the PASCAL Precision system to clinicians in Europe marks another significant step in our partnership with physicians who treat the large population of patients with mitral and tricuspid valve disease," said Bernard J. Zovighian, Edwards' corporate vice president, transcatheter mitral and tricuspid therapies.

  3. Show article details.

    Edwards Lifesciences Whale Trades Spotted

    Benzinga – 5:13 PM ET 08/05/2022

    Someone with a lot of money to spend has taken a bullish stance on Edwards Lifesciences. And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know. So how do we know what this whale just did?

  4. Show article details.

    Analyzing Edwards Lifesciences's Short Interest

    Benzinga – 12:06 PM ET 08/03/2022

    Edwards Lifesciences's short percent of float has risen 6.93% since its last report. Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock.

  5. Show article details.

    Here's How Much $100 Invested In Edwards Lifesciences 10 Years Ago Would Be Worth Today

    Benzinga – 2:38 PM ET 07/29/2022

    Edwards Lifesciences has outperformed the market over the past 10 years by 8.15% on an annualized basis producing an average annual return of 19.8%. Currently, Edwards Lifesciences has a market capitalization of $62.66 billion. Buying $100 In EW: If an investor had bought $100 of EW stock 10 years ago, it would be worth $604.44 today based on a price of $100.78 for EW at the time of writing.

  6. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022

    Benzinga – 10:31 AM ET 07/29/2022

      See all analyst ratings upgrades.   See all analyst ratings downgrades.   See all analyst ratings initiations.

  7. Show article details.

    Roku, Intel And Some Other Big Stocks Moving Lower In Today's Pre-Market Session

    Benzinga – 8:13 AM ET 07/29/2022

  8. Show article details.

    12 Health Care Stocks Moving In Thursday's After-Market Session

    Benzinga – 6:04 PM ET 07/28/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

  9. Show article details.

    BRIEF-Edwards Lifesciences Reports Second Quarter Results

    Reuters – 4:58 PM ET 07/28/2022

    Edwards Lifesciences Corp (EW): * EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS. * Q2 ADJUSTED EARNINGS PER SHARE $0.63. * Q2 EARNINGS PER SHARE $0.65. * Q2 SALES $1.37 BILLION. * CONTINUES TO ESTIMATE THAT GLOBAL TAVR OPPORTUNITY WILL DOUBLE TO $10 BILLION BY 2028. * EXPECTS APPROXIMATELY 10 PERCENT UNDERLYING SALES GROWTH IN SECOND HALF OF YEAR.

  10. Show article details.

    Edwards Lifesciences Shares Slide As Q2 Results Miss Expectations, Lowers FY22 Sales Outlook

    Benzinga – 4:54 PM ET 07/28/2022

    Edwards Lifesciences Shares Slide As Q2 Results Miss Expectations, Lowers FY22 Sales Outlook

  11. Show article details.

    Recap: Edwards Lifesciences Q2 Earnings

    Benzinga – 4:37 PM ET 07/28/2022

    Edwards Lifesciences reported its Q2 earnings results on Thursday, July 28, 2022 at 04:15 PM. Here's what investors need to know about the announcement. Edwards Lifesciences missed estimated earnings by 1.56%, reporting an EPS of $0.63 versus an estimate of $0.64. Revenue was down $2.00 million from the same period last year.

  12. Show article details.

    BRIEF-Edwards Lifesciences Corp - Expect Strong Double-Digit Adjusted Eps Growth In Second Half Of The Year

    Reuters – 4:26 PM ET 07/28/2022

    Edwards Lifesciences Corp (EW): * Edwards Lifesciences Corp (EW) - EXPECTS ABOUT 10% UNDERLYING SALES GROWTH IN SECOND HALF OF YEAR. * Edwards Lifesciences Corp (EW) - EXPECT STRONG DOUBLE-DIGIT ADJUSTED EPS GROWTH IN SECOND HALF OF THE YEAR. * Edwards Lifesciences Corp (EW) - FOR TOTAL EDWARDS, NOW EXPECTS FULL YEAR 2022 SALES OF $5.35 BILLION TO $5.55 BILLION.

  13. Show article details.

    EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS

    PR Newswire – 4:15 PM ET 07/28/2022

    IRVINE, Calif. Second Quarter Highlights and Outlook "We continue to expect meaningful progress in 2022 on our pursuit of innovative therapies that address significant unmet patient needs. Transcatheter Aortic Valve Replacement In the second quarter, the company reported TAVR sales of $907 million, a year-over-year increase of 1 percent, or 5 percent on an underlying basis.

  14. Show article details.

    10 Health Care Stocks Whale Activity In Today's Session

    Benzinga – 1:37 PM ET 07/28/2022

      This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth.

  15. Show article details.

    Earnings Scheduled For July 28, 2022

    Benzinga – 6:06 AM ET 07/28/2022

      ** ArcelorMittal is estimated to report earnings for its second quarter. ** argenx is likely to report quarterly loss at $4.83 per share on revenue of $37.85 million. ** ASE Technology Holding Co is estimated to report quarterly earnings at $0.20 per share on revenue of $5.08 billion. ** Barclays is estimated to report earnings for its second quarter.

  16. Show article details.

    Earnings Scheduled For July 28, 2022

    Benzinga – 5:06 AM ET 07/28/2022

      ** ArcelorMittal is estimated to report earnings for its second quarter. ** argenx is likely to report quarterly loss at $4.83 per share on revenue of $37.85 million. ** ASE Technology Holding Co is estimated to report quarterly earnings at $0.20 per share on revenue of $5.08 billion. ** Barclays is estimated to report earnings for its second quarter.

  17. Show article details.

    BRIEF-Edwards Lifesciences Files For Potential Mixed Shelf Offering; Size Not Disclosed

    Reuters – 11:57 AM ET 07/22/2022

    Edwards Lifesciences Corp (EW): * EDWARDS LIFESCIENCES CORP FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text - https://bit.ly/3aZcI0w Further company coverage:

  18. Show article details.

    BRIEF-Edwards Lifesciences Says Entered Into Credit Agreement To Establish New 5-Year $750 Mln Multi-Currency Unsecured Revolving Credit Facility

    Reuters – 5:25 PM ET 07/21/2022

    Edwards Lifesciences Corp (EW): * Edwards Lifesciences Corp (EW)- ON JULY 15 ENTERED INTO CREDIT AGREEMENT TO ESTABLISH NEW 5-YEAR $750 MILLION MULTI-CURRENCY UNSECURED REVOLVING CREDIT FACILITY. * Edwards Lifesciences Corp (EW)- NEW REVOLVING FACILITY REPLACES EXISTING $750 MILLION UNSECURED REVOLVING CREDIT FACILITY UNDER THE 2018 CREDIT AGREEMENT Source: Further company coverage:

  19. Show article details.

    EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 28, 2022

    PR Newswire – 7:05 AM ET 07/21/2022

    IRVINE, Calif. To participate in the conference call, dial 704-2848 or 389-0893. About Edwards LifesciencesEdwards Lifesciences (EW), is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. Edwards, Edwards Lifesciences (EW), and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

  20. Show article details.

    Expert Ratings for Edwards Lifesciences

    Benzinga – 4:53 PM ET 07/18/2022

    Analysts have provided the following ratings for Edwards Lifesciences within the last quarter: In the last 3 months, 7 analysts have offered 12-month price targets for Edwards Lifesciences. Below is a summary of how these 7 analysts rated Edwards Lifesciences over the past 3 months.

Page:

Today's and Upcoming Events

  • Oct
    25

    EW to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Jul
    28

    EW announced Q2 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.